Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.53 (sialidase)
 2,694 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The lysosome is an intracytoplasmic acidic vacuole containing more than 60 hydrolytic enzymes for digestion of macromolecules, such as nucleic acids, proteins, lipids and complex carbohydrates. Expression of lysosomal enzyme activities is regulated by various intracellular environmental factors. Mutation of a gene coding for a lysosomal enzyme results in a specific genetic disease, often involving the central nervous system in children. Three groups of functional proteins are known at present for regulation of the expressed enzyme activity in lysosomes. Targeting of a newly synthesized protein is achieved by the mannose 6-phosphate receptor system, which was revealed in the course of I -cell disease research. Many lysosomal enzymes are excessively secreted in the extracellular compartment in the absence of this regulatory system in patients with this disease. Intralysosomal stability of beta-galactosidase is regulated by a multifunctional protein that interacts with two lysosomal enzymes, beta-galactosidase and sialidase, and also exerts catalytic activities as carboxypeptidase, esterase and deamidase under various pH conditions. It is encoded by a gene on chromosome 20, and its mutation results in a neurodegenerative disease in children and adults (galactosialidosis). For digestion of lipid substrates, lysosomal enzymes need specific activator proteins as natural detergents for molecular interaction with these nonpolar compounds. Two different groups of proteins have been revealed. A protein encoded by a gene on chromosome 5 interacts with ganglioside GM2 and its asialo derivative, for their catalytic hydrolysis by beta-hexosaminidase A. Another protein encoded by a gene on chromosome 10 is expressed as a precursor (prosaposin) which is then processed to four small proteins (saposins) with heterogeneous functions. They are essential for hydrolysis of sphingolipid substrates, and genetic deficiency of each protein results in various lipid storage diseases.
 ...
PMID:[Lysosomal enzymes, sphingolipid activator proteins, and protective protein]. 857 30

Transcobalamin II-receptor (TC II-R) contains 10 half-cysteines, of which 8 are involved in intramolecular disulfide bonding. Reduction followed by alkylation with N-ethylmaleimide (NEM) of the 62-kDa TC II-R monomer in vitro or treatment of human intestinal epithelial Caco-2 cells with low concentrations (10(-6) M) of NEM resulted in TC II-R exhibiting a loss of ligand binding and an increase in its apparent molecular mass by 10 kDa to 72 kDa. Domain-specific biotinylation studies using NEM-treated filter-grown cells revealed loss of TC II-R but not cation-independent mannose 6-phosphate receptor protein at the basolateral cell surface. Pulse-chase labeling of NEM-treated cells with [35S]methionine revealed that the modified 72-kDa TC II-R, like the native 62-kDa TC II-R in untreated cells, turned over rapidly with a t1/2 of 7.5 h and was sensitive to treatment with peptide N-glycosidase F, sialidase alone, or sialidase and O-glycanase but not to treatment with endoglycosidase H. Labeled 72-kDa TC II-R, which was retained intracellularly following treatment of Caco-2 cells with methyl methanethiosulfonate, returned to the basolateral cell surface following withdrawal of cells from methyl methanethiosulfonate treatment and exposure to dithiothreitol. Based on these results, we suggest that formation and maintenance of intramolecular disulfide bonds of TC II-R is important for its acquisition of ligand binding and post-trans-Golgi trafficking to basolateral surface membranes but not for its turnover and exit from the endoplasmic reticulum or trafficking through the Golgi.
 ...
PMID:Effect of disulfide bonds of transcobalamin II receptor on its activity and basolateral targeting in human intestinal epithelial Caco-2 cells. 925 20

Three different mammalian sialidases have been described as follows: lysosomal (Neu1, gene NEU1), cytoplasmic (Neu2, gene NEU2), and plasma membrane (Neu3, gene NEU3). Because of mutations in the NEU1 gene, the inherited deficiency of Neu1 in humans causes the severe multisystemic neurodegenerative disorder sialidosis. Galactosialidosis, a clinically similar disorder, is caused by the secondary Neu1 deficiency because of genetic defects in cathepsin A that form a complex with Neu1 and activate it. In this study we describe a novel lysosomal lumen sialidase encoded by the NEU4 gene on human chromosome 2. We demonstrate that Neu4 is ubiquitously expressed in human tissues and has broad substrate specificity by being active against sialylated oligosaccharides, glycoproteins, and gangliosides. In contrast to Neu1, Neu4 is targeted to lysosomes by the mannose 6-phosphate receptor and does not require association with other proteins for enzymatic activity. Expression of Neu4 in the cells of sialidosis and galactosialidosis patients results in clearance of storage materials from lysosomes suggesting that Neu4 may be useful for developing new therapies for these conditions.
 ...
PMID:Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells. 1521 28